Late-Breaking Abstract Submission Guidelines

**For any difficulties with abstract submissions, please contact**

Key Dates
Late-breaking submission deadline March 23, 2018, 11:59 pm EST
Notification to authors April 2 - 6, 2018
Late-breaking presenter registration deadline April 20, 2018

Please carefully read the following guidelines and review the sample abstract prior to submitting an abstract online.

  • Rules for authors
    • The abstracts must not have been published before. Note that selected abstracts will be published as a supplement in Haemophilia journal, the official Congress Book of Abstracts.

    • Rule of Two: Each author may present a maximum of two abstracts at the Congress. However, authors can make an unlimited number of submissions. Should an author have more than two abstracts accepted, a co-author must be named as the presenting author for the third or more abstracts.

    • All presenting authors must be paid registrants of the WFH 2018 World Congress by March 23, 2018, for regular abstracts and April 20, 2018, for late-breaking abstracts. After this date, presenting authors who have not paid their registration fees will be excluded from the program, as well as from the Book of Abstracts.

    • The submission of an abstract carries with it the obligation that it will be presented at the Congress by the presenting author. Failure to present as scheduled may result in the non-acceptance of future submissions at WFH meetings.

    • Each abstract will be blinded and scored by three reviewers. Abstracts will be accepted based on the following criteria: relevance; interpretation of results; originality and novelty; organization; and clarity.

    • Abstracts may not be revised or resubmitted after the deadline date of March 23, 2018.

    • Please submit abstract withdrawal requests in writing by March 23, 2018.

    • Please submit change of presenting author requests in writing by March 23, 2018. After this date, changes will not appear in the Book of Abstracts.
  • Preparation of abstracts
    • Abstracts should be clear, concise, and written and presented in English. Abstracts will be published as submitted. Presenters are requested to carefully proofread their abstract. The Congress Program Committee reserves the right to reject abstracts that are deemed to be poorly written or to request an immediate revision of the text to improve its readability.

    • Abstracts should not exceed 350 words. When calculating your word count, please note that every table or graph in your abstract counts as 50 words.

    • Images are NOT permitted.

    • Be sure to indicate the appropriate topic category when submitting your abstract to ensure proper consideration.

    • Choose a preferred presentation type (oral or poster). The Congress Program Committee will determine whether the abstract will be accepted as a free paper, moderated poster, or a poster, with consideration given to the author’s preference, available time, and fit in the Congress program.

    • Your abstract must include the following sections:

      Introduction and Objective
      Materials and Methods

    • Do NOT include references, credits or grant support in your abstract

    • The abstract that you upload MUST NOT include the author list. Authors and affiliations are to be submitted on the on-line form only. Only one presenting author is permitted per submission.

    • If an author’s name appears on more than one abstract, it must be written in the same way on each abstract to ensure proper indexing

    • Abstracts that describe single clinical cases, or lack quantitative data will NOT be accepted. Authors are NOT to split data to create several abstracts from one. If “splitting” has been judged to have occurred, the priority scores of related abstracts will be reduced.
  • Formating
    • Use a short, specific title for your abstract. The title should be entered in sentence case. Do not use a period at the end of the title and do not place the title in quotes nor use ALL CAPS.

    • Capitalize the first letter of trade names.

    • Do NOT use ALL CAPS in the title or in the body text.

    • Use standard abbreviations for units of measure. Other abbreviations should be spelled out in full at first mention, followed by the abbreviation in parenthesis (exceptions: RNA, DNA, etc.).

    • Special Characters: Please use the special character palate if you need to use a special character. If you copy and paste your abstract, please be sure to enter special characters using the palette, even if they seem to appear correctly after pasting. If you do not use the special palette, your special characters will not appear properly in publication. Please be sure to double-check during proofreading to ensure all special characters were converted properly.

    • Do not attach tables, charts, illustrations, or additional figures.
  • Sample Abstract
    Predictors of response to combination therapy with recombinant factor VIIa and factor VIII in patients with hemophilia A and high titer inhibitors

    Introduction and Objectives: Although the use of bypassing agents has significantly improved the treatment of hemophilia A patients who develop inhibitors, some patients, for unknown reasons, have a poor hemostatic response to bypass therapy. Improved treatment options for patients with inhibitors are needed. Studies from our laboratory and others have shown that even small amount of factor VIII (fVIII) activity can vastly improve the thrombin generation (TG) capability of recombinant factor VIIa (fVIIa) in patients with hemophilia A and inhibitors. Materials and Methods: Plasma from patients with congenital hemophilia A and high titer inhibitors was available from our IRB approved inhibitor bank. Each plasma sample was evaluated for response to 2 U/ml fVIII (~100 U/kg dosing) with and without 2.25 mcg/ml rfVIIa in a thrombin generation assay. Residual fVIII activity at 15 minutes after addition of 2 U/ml fVIII was measured using a one-stage coagulation assay. Results: 15 different patients with inhibitor titers ranging from 5.2-109 BU/ml were tested. In the 10 patients with inhibitor titers of 5.2-28 BU/ml only 1 patient with a titer of 20 BU/ml did not respond to fVIII supplementation. In the 5 patients with inhibitor titers >42 BU/ml, there was no increase in TG. A second specimen was available for 4 patients. All 3 patients who had increased TG in the presence of fVIII continued to have increased TG in the second specimen despite up to a 2-fold difference in inhibitor titer. A subset of 10 patients also had residual fVIII activity testing. In this group, residual fVIII activity strongly correlated with peak TG (r⊃; = 0.86, p>0.001) and also correlated with ETP (r⊃; = 0.54, p=0.04). Conclusions: The majority of patients with hemophilia A and high titer inhibitors have improved TG with combined use of fVIII and rfVIIa over rfVIIa alone. Residual fVIII activity at 15 minutes was a predictor of both peak thrombin generation and ETP. An inhibitor titer above 42 BU/ml was associated with no response.
  • Abstract notification
    The notification of acceptance for late-breaking abstracts will be sent between April 2-6, 2018.

    Please note that only the corresponding author will be contacted concerning the abstract, and so the corresponding author is responsible for informing all co-authors of the status of the abstract.
  • Authorization to publish
    Submission of the abstract constitutes permission for the WFH to publish the abstracts in either print or electronic format.
  • Abstract Public Release (Embargo)
    Late-breaking abstracts (LBAs) will be publicly released throughout the WFH 2018 World Congress. The complete embargo dates and public release schedule for LBAs is detailed here. All other abstracts—including those submitted during the late-breaking submission time period but not selected as late-breaking abstracts—will be publicly released online at 9:00 a.m. EST on May 10, 2018.
  • Conflict of interest disclosure
    The WFH requires authors to identify any significant conflicts of interest and all outside sources of funding. Authors must include any disclosures at the end of the abstract. Please note that the disclosure word count does not count towards the total abstract word count.
  • Submission page
    Please click here for the submission page.

    Once you have created a profile in the Congress online system, you can submit one or several abstracts from your account. After an abstract has been created, modifications can be made until the abstract submission deadline. Please note that you cannot create another account if you have previously created one. If you need to retrieve your user name and password, please click on the lost or forgotten password button when signing in to the submission page.
  • Registration
    Please note that all poster and free paper presenters must register as delegates for the WFH 2018 World Congress. To register online, please click here.

The WFH 2018 World Congress is supported by the Glasgow City
Council and VisitScotland

Submit your abstract

© World Federation of Hemophilia